EMEA-003516-PIP01-23

Start of procedure: Extension of marketing authorisation (28 February 2025 - 27 March 2025)

Start of procedure: Type II variation - extension of indication under evaluation by the CHMP (28 February 2025 - 27 March 2025)

Scientific advice and protocol assistance adopted during the CHMP meeting 24-27 March 2025

Procedural guidance to scientific committeesꞌ members and experts on completing the European Medicines Agencyꞌs declaration of interests in the Experts Management Tool

ICMRA Summit 2025, European Medicines Agency, Amsterdam, the Netherlands, from 21 October 2025 to 24 October 2025

Herbal medicinal product: Salicis cortex, Salix [various species including S. purpurea L.; S. daphnoides Vill.; S. fragilis L.], F: Assessment finalised

Herbal medicinal product: Psyllii semen, Plantago afra L.,Plantago indica L., F: Assessment finalised

Herbal medicinal product: Harpagophyti radix, Harpagophytum procumbens DC.; Harpagophytum zeyheri Decne, F: Assessment finalised

Herbal medicinal product: Hamamelidis cortex, Hamamelis virginiana L., F: Assessment finalised